PATENT CLAIM ANALYSIS

Application Number: 15866759
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-09
Patent Classification: ["424", "130100"]

Abstract:
Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (CAT). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.

Claim (Index 6):
The antibody of  claim 5 , wherein the antibody is at least one of a monoclonal, polyclonal, fully human, humanized, chimeric, single-chain, or anti-idiotypic antibody.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 86.0
- Lexical Diversity: 2.11475
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11802321', '12901254', '12504826', '13670293', '11635029']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7762293462899291
- 35 USC 102 Novelty (BERT): 0.5406142087533707
- Combined Prediction Score: 0.7526678325362732
- Mean Citation Score: 328.435412
- Max Citation Score: 404.3128
- Similarity Product: 227.7301747764588

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test